Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel guanidine mimics as factor Xa inhibitors

An atomistic, compound-based technique applied in the field of novel guanidine mimetics as factor Xa inhibitors, able to resolve unspecified issues, etc.

Inactive Publication Date: 2000-07-12
BRISTOL MYERS SQUIBB PHARMA CO
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Baker et al. do not indicate that A can be a substituted ring system contained in the presently claimed heteroaromatic compounds of the present invention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel guanidine mimics as factor Xa inhibitors
  • Novel guanidine mimics as factor Xa inhibitors

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0217] Scheme 6 illustrates the preparation method of aminobenzimidazole aldehyde, which can be joined to a C-linked or N-linked heterocyclic ring according to the method described in the synthesis section later. Cyclization of 3,4-diaminobenzoate gives cbz-protected 2-aminobenzimidazole, followed by DIBAL reduction and oxidation to give the desired aldehyde.

[0218] Process 6

[0219] Scheme 7 describes the preparation method of N-linked aminobenzisoxazole, aminoindazole, diaminoquinazoline and aminoquinazoline of formula I. At room temperature to the reflux temperature of the selected solvent, in protic or aprotic solvents (with or without miscible co-solvents), use stannous chloride or other suitable reducing agents, commercially available The aniline derivatives prepared from 2-fluoro-5-nitrobenzonitrile can be used to prepare this type of compound.

[0220] According to the foregoing, N-linked 3-aminobenzisoxazole and 3-aminoindazole can be obtained. By...

Embodiment 1

[0354] Example 11-(1'-Amino-isoquinolin-7'-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)

[0355] Carbonylamino]pyrazole, methanesulfonate

[0356] At 0°C, 7-aminoisoquinine (6.26 g, 43.4 mmol) (J. Chem. Soc. 1951, 2851) was added to 40 ml of concentrated hydrochloric acid. Sodium nitrite (3.0g, 43.4mmol) was dissolved in 15ml of water, cooled to 0°C and added dropwise to the above isoquinine solution. The reaction was stirred at 0°C for 30 minutes. Dissolve stannous chloride dihydrate (29.3g, 130.2mmol, 3eq) in 25ml of concentrated hydrochloric acid, cool the solution to 0°C, and add dropwise to the above isoquinine solution. The reaction was placed in the refrigerator overnight. The precipitate was separated by filtration the next day, washed with 100 ml of ice-cold brine, followed by 100 ml of a 2:1 petroleum ether / diethyl ether solution. The brown solid was dried under dynamic vacuum overnight. The tin double salt of isoqui...

Embodiment 21

[0361] Example 21-(1'-Amino-isoquinolin-7'-yl)-3-methyl-5-[(2'-methanesulfonyl-[1,1']-biphenyl-4-yl) carbonyl

[0362] Amino]pyrazole methanesulfonate

[0363] According to a method similar to that described in Example 1, the target compound was prepared. MS(ES+): 498.0(M+H) + (100%), mp 175°C.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Relative strengthaaaaaaaaaa
Relative strengthaaaaaaaaaa
Relative strengthaaaaaaaaaa
Login to View More

Abstract

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula (I) or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.

Description

Invention field [0001] The present invention generally relates to novel guanidine mimetics that are trypsin-like serine proteases (especially factor Xa) inhibitors, pharmaceutical compositions containing them, and methods of using them as anticoagulants to treat and prevent thrombotic diseases. Background of the invention [0002] WO 96 / 28427 describes benzamidine anticoagulants of the following formula: Where Z 1 And Z 2 O, N(R), S, or OCH 2 , The central ring can be a phenyl group or various heterocyclic rings. The compound we currently require does not contain Z 1 The linking group or the type of substitution of the above compound. [0003] WO 95 / 13155 and PCT International Application US 96 / 07692 describe isoxazoline and isoxazole fibrinogen receptor antagonists of the following formula: Where R 1 It can be a basic group, U-V can be a six-membered aromatic ring, W-X can be various linear or cyclic groups, and Y is an oxygen-containing group. Therefore, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D487/04A61K31/416A61K31/42A61K31/422A61K31/423A61K31/437A61K31/4375A61K31/4439A61K31/4709A61K31/4725A61K31/498A61K31/502A61K31/517A61K31/519A61K31/5377A61P7/02A61P9/10C07D231/14C07D231/56C07D261/20C07D401/04C07D401/14C07D403/04C07D403/14C07D413/04C07D413/14C07D471/04C07D498/04C07D513/04C07D521/00
CPCC07D401/14C07D413/04C07D413/14C07D403/04C07D231/12C07D261/20C07D249/08C07D231/56C07D231/14C07D233/56C07D401/04A61P11/00A61P13/12A61P43/00A61P7/00A61P7/02A61P9/00A61P9/10
Inventor P·Y·林C·G·克拉克C·多明格兹J·M·菲维格Q·韩R·李D·J·P·平托J·R·普瑞特M·L·荃
Owner BRISTOL MYERS SQUIBB PHARMA CO